Frankfurt
20.03.26 | 08:55
4,720 Euro
-3,67 % -0,180
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,720 | 4,840 | 18:58 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Mi | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| Mi | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA TO PRESENT DATA FROM FOUR PRECLINICAL STUDIES IN ITS INNOVATIVE PIPELINE AT AMERICAN ASSOCIATION ... | 1 | HKEx | ||
| 13.03. | ASCENTAGE-B (06855): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 11.03. | BTIG initiates Ascentage Pharma stock coverage with buy rating | 1 | Investing.com | ||
| 11.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 11.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026 | 2 | GlobeNewswire (USA) | ||
| 23.02. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
| 12.02. | Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target | 2 | Insider Monkey | ||
| 06.02. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.02. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 | 289 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company... ► Artikel lesen | |
| 15.01. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.01. | Rodman & Renshaw initiates coverage on Ascentage Pharma stock with Buy rating | 3 | Investing.com | ||
| 07.01. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.01. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 | 334 | GlobeNewswire (Europe) | Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the... ► Artikel lesen | |
| 31.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.12.25 | ASCENTAGE-B (06855): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 30.12.25 | ASCENTAGE-B (06855): (1) CHANGE IN COMPOSITION OF NOMINATION COMMITTEE; (2) APPOINTMENT OF LEAD INDEPENDENT NON-EXECUTIVE DIRECTOR; (3) ESTABLISHMENT ... | 2 | HKEx | ||
| 17.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 09.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,759 | +1,24 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 27,835 | -0,50 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| EDITAS MEDICINE | 2,053 | +1,68 % | Is Editas Medicine Going to $0? | ||
| SAREPTA THERAPEUTICS | 14,710 | +1,62 % | Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies | ||
| EXACT SCIENCES | 90,94 | +0,22 % | Abbott to close $21B Exact Sciences deal on March 23 | ||
| BASILEA | 56,90 | -0,70 % | BANCO BILBAO VIZCAYA ARGENTARIA, S.A.: The Company reports the 2025 "Prudential Relevance Report" (Pilar III Basilea) | ||
| TELIX PHARMACEUTICALS | 8,008 | +2,01 % | IBA SA: Telix selects IBA Cyclone KIUBE to support manufacturing expansion in the U.S. | Louvain-la-Neuve, Belgium- March 20, 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical... ► Artikel lesen | |
| REPLIGEN | 97,00 | -0,47 % | Repligen Corporation: Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year... ► Artikel lesen | |
| UNIQURE | 13,755 | -1,43 % | uniQure Inc.: uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease | LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| CODEXIS | 1,355 | -2,38 % | Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform | REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 36,000 | +6,51 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated... ► Artikel lesen | |
| MACROGENICS | 2,426 | -1,78 % | MacroGenics, Inc.: MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures | Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030... ► Artikel lesen | |
| OMEROS | 9,600 | +0,52 % | Omeros Corporation: Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment | Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22,... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,040 | -0,73 % | Spero Therapeutics, Inc.: Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 | ||
| KALVISTA PHARMACEUTICALS | 14,700 | -0,68 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference | New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced... ► Artikel lesen |
Das Unternehmen ASCENTAGE PHARMA GROUP INTERNATIONAL kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,720 Euro und damit -3,67 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL finden Sie auf Wallstreet Online.